Mineral and Electrolyte Disorders With SGLT2i Therapy

The newly developed sodium‐glucose cotransporter 2 inhibitors (SGLT2is) effectively modulate glucose metabolism in diabetes. Although clinical data suggest that SGLT2is (empagliflozin, dapagliflozin, ertugliflozin, canagliflozin, ipragliflozin) are safe and protect against renal and cardiovascular e...

Descripción completa

Detalles Bibliográficos
Autores principales: Cianciolo, Giuseppe, De Pascalis, Antonio, Capelli, Irene, Gasperoni, Lorenzo, Di Lullo, Luca, Bellasi, Antonio, La Manna, Gaetano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874177/
https://www.ncbi.nlm.nih.gov/pubmed/31768494
http://dx.doi.org/10.1002/jbm4.10242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874177/
https://www.ncbi.nlm.nih.gov/pubmed/31768494
http://dx.doi.org/10.1002/jbm4.10242

Ejemplares similares